At ESMO today, I presented the long-term survival results of Fianlimab and Simiplumab in advanced melanoma. Fianlimab is a LAG3 inhibitor. Simiplumab is a PD-1 inhibitor. These are combination checkpoint inhibitors. And in melanoma, we have approval of a similar combination. This is the follow-up in the subset of patients in the phase 1, 16, 13 study to look at how they are many years later...
At ESMO today, I presented the long-term survival results of Fianlimab and Simiplumab in advanced melanoma. Fianlimab is a LAG3 inhibitor. Simiplumab is a PD-1 inhibitor. These are combination checkpoint inhibitors. And in melanoma, we have approval of a similar combination. This is the follow-up in the subset of patients in the phase 1, 16, 13 study to look at how they are many years later. We have about 90-plus patients treated in three separate cohorts. One was previously treated melanoma in the advanced setting that hadn’t seen PD-1, untreated melanoma in the advanced setting, and treated with adjuvant therapy with recurrence. And this data has been presented and published in JCO. What hasn’t been published is the long-term data where we’re seeing in a subset of patients that we continue to follow through, that survival is what we expected, which is a plateau. So long-term survival, 60%. What we’re seeing is no new toxicity signals. We’re seeing a very tolerable regimen. And then what we looked at in this combination was circulating tumor DNA, understanding that at nine weeks and 12 weeks, circulating tumor DNA that has decreased and has resolved is the subset that’s getting the greatest benefit. So as we look to melanoma to inform other solid tumors, this is a new target. This is a new predictor. Whether you’re cleared with checkpoint inhibition, your CT DNA, this is a long-term survival. What we’ve also known and what this data supports is that at three years, your progression-free survival, if you haven’t progressed, these are the patients who have long-term benefit. We’ve seen this in checkpoint 067, that if you haven’t progressed at three years, you’re not going to progress over 95%. These are important time points to correlate to other solid tumors. Again, with this combination, there are randomized trials ongoing in the metastatic setting in comparison to an approved LAG3 PD-1 combination. And there are adjuvant studies that are randomized and accrued to see if there is a benefit of adding LAG-3 in the adjuvant setting. And in addition, this is a viable neoadjuvant regimen. LAG-3 is associated with T-cell exhaustion and also lack of response resistance to PD-1 therapy. And what we’ve seen as a group is it’s best to be introduced early. So what do we have now that we’re looking forward to? Well, we’re looking forward to triplet regimens. And of note, there is one ongoing. It’s the combination of Fianlimab, Simiplumab, and Ipilimumab. So anti-CTLA-4 checkpoint inhibition in refractory patients that have seen single agent PD-1 or anti-PD-1 and anti-CTLA-4. And these are important to understand in patients who are refractory even to adjuvant anti-PD-1. We need answers here. My hope is that in some way we find a role for this combination and then look for it in earlier disease and in combinations with things that are now looking more promising in melanoma, whether it be ADCs, TIL therapy, et cetera. So we have a lot that we have gained from the data here in this combination, and we have a lot more to do as we leave ESMO.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.